$KURA News

Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win

Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript

Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow

Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Kura Oncology And Kyowa Kirin Announce Long-Term Results From The Phase 1/2 KOMET-007 Single-Arm Trial Evaluating Ziftomenib In Combination With Intensive Chemotherapy

How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions

Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib - Slideshow

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcript

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Kura Oncology Highlights New Clinical And Translational Data Supporting Darlifarnib As Potential Foundational Combination Platform For KRAS-Mutant Cancers And Other Targeted Therapy Settings

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Showing 87% ORR In Venetoclax-Naïve R/R NPM1-m AML

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

Kura Oncology Announces First-In-Human Data From The FIT-001 Clinical Trial Of Darlifarnib In Combination With Adagrasib In Heavily Pretreated Patients With KRAS G12C-Mutated Advanced Solid Tumors

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates

Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Trimming Their Forecasts